New target for HIV/AIDS drugs and vaccines discoveredJuly 27, 2007Bethesda, MD--Researchers from Rome, Italy, describe a finding in the August 2007 print issue of The FASEB Journal that could lead to new drugs to fight the HIV/AIDS virus, as well as new vaccines to prevent infection. It has been known that HIV proteins disable the antibody-forming part of the immune system (the "homeland defense" or acquired immune system). In this report, researchers demonstrate for the first time how the HIV-1 Nef viral protein delivers a one-two punch to the body's innate immune system (our "early warning system" composed of dendritic and natural killer cells). First, Nef hijacks dendritic cells (DCs) to upset the function of natural killer (NK) cells. Second, after blocking this first line of defense against the immune system, Nef uses DCs and NK cells to create a microenvironment that actually makes it easier for HIV/AIDS to replicate. According to Maria Giovanna Quaranta of Instituto Superiore de Sanità and first author of the article, "The findings described in this work may have several implications for AIDS treatment: the understanding of Nef function, mechanism of action, and cellular partners might aid the discovery of suitable drugs able to block the activity of this smart protein." Quaranta added, "An exciting possibility is the design of a vaccine including a mutated Nef protein unable to assist the virus in the control of its host." The research findings also raise another intriguing possibility: Nef proteins may be able to boost or suppress DC and NK cell activity. If so, it may prove to be a valuable new therapeutic approach for people with diseases and disorders that involve overactive or underactive immune responses. DCs and NK cells play critical roles in the body's initial defense against infection. DCs are instrumental in identifying foreign invaders to the body and then orchestrating an immune response that ultimately removes them. NK cells are among the first cells summoned by DCs to help isolate and contain the infection until more potent reinforcements can be manufactured to eradicate the virus or bacteria. When DC cells can no longer adequately "manage" the immune response and when NK cells can no longer contain infections, the likelihood of survival without medical intervention is relatively low.
"HIV's relatively rapid evolution has given it an ability to handle all our bodies can throw at it and more," said Gerald Weissmann, MD, Editor-in-Chief of The FASEB Journal. "Now that we know how the viral protein disables the innate as well as the acquired arm of our immune system, we can begin to design decoy proteins or to devise new vaccines. Millions of lives depend on our finding a way to restore both aspects of our immune defense against HIV/AIDS-this study should go a long way toward that goal." The FASEB Journal is published by the Federation of American Societies for Experimental Biology (FASEB) and is consistently ranked among the top three biology journals worldwide by the Institute for Scientific Information. FASEB comprises 21 nonprofit societies with more than 80,000 members, making it the largest coalition of biomedical research associations in the United States. FASEB advances biological science through collaborative advocacy for research policies that promote scientific progress and education and lead to improvements in human health. The Federation of American Societies for Experimental Biology | |||||||||||||||||||||
|
Related HIV/AIDS Current Events and HIV/AIDS News Articles First Holistic Guide to Primate Disease Covers Critical Gap in Global Health Why are so many infectious diseases jumping from animals to humans? Why do we have so little capacity to predict epidemics, or avoid them? Applying 'supply and demand' business principles to treat infectious diseases worldwide Treating infectious diseases while meeting escalating costs to do so continues to pose worldwide challenges, with one of the main issues being the ability to provide an adequate supply of drugs to treat infectious diseases. T cell-based HIV vaccine candidate demonstrates positive results The question of whether or not to continue to pursue the development of T-cell-based HIV-1 vaccines has been a source of controversy following last year's widely publicized failure of the field's most promising candidate, a vaccine developed by Merck known as V520. New study shows that important gene controls the ability of the thymus to produce disease-fighting T-cells after an organism's birth New research, just published by researchers from the University of Georgia, provides the first evidence that a key gene may be crucial to maintaining the production of the thymus and its disease-fighting T-cells after an animal's birth. New HIV-reduction initiative takes to the fields Education has found its way onto the soccer fields of North Carolina - in the form of a social experiment that may have all the right ingredients to change the direction of Latino health in the United States. Rapid HIV testing in the ER boosts diagnoses, screening One in every 50 people screened for a suspected sexually transmitted infection (STI) in the Emergency Department at Henry Ford Hospital was found to be infected with HIV using a rapid blood sample screening test. Markers of inflammation and blood-clotting tied to hazards of intermittent HIV treatment Episodic treatment of HIV/AIDS with antiretroviral drugs increases the overall risk of death when compared with continuous antiretroviral treatment (ART), but the reasons why have been unknown. Researchers estimate lives lost due to delay in antiretroviral drug use for HIV/AIDS in South Africa More than 330,000 lives were lost to HIV/AIDS in South Africa from 2000 and 2005 because a feasible and timely antiretroviral (ARV) treatment program was not implemented, assert researchers from the Harvard School of Public Health (HSPH) in a study published online by the Journal of Acquired Immune Deficiency Syndromes (JAIDS) (http://www.jaids.com/). Efavirenz-Based Initial Therapies Associated with Better Outcomes in HIV-Infected Adults A study led by researchers at the Johns Hopkins Bloomberg School of Public Health found that HIV-infected patients taking the antiretroviral drug efavirenz were more likely to adhere to treatment and less likely to experience virologic failure and death compared to patients taking nevirapine. New research on family-based HIV prevention presented at annual NIH conference Researchers from the Bradley Hasbro Children's Research Center (BHCRC) presented exciting new research today at the National Institute of Mental Health (NIMH) Annual International Research Conference on the Role of Families in Preventing and Adapting to HIV/AIDS. More HIV/AIDS Current Events and HIV/AIDS News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||